203. 22q11.2 deletion syndrome Clinical trials / Disease details
Clinical trials : 5 / Drugs : 7 - (DrugBank : 1) / Drug target genes : 14 - Drug target pathways : 23
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04647500 (ClinicalTrials.gov) | August 26, 2016 | 3/11/2020 | Effects of Methylphenidate on Brain and Cognition in 22q11 Deletion Syndrome | Effects of Modulation of the Dopaminergic System Using Methylphenidate on Memory and Executive Processes in Individuals With 22q11.2 Deletion Syndrome | 22q11.2 Deletion Syndrome | Drug: Concerta | University of Geneva, Switzerland | NULL | Recruiting | 8 Years | 25 Years | All | 30 | N/A | Switzerland |